Profile data is unavailable for this security.
About the company
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
- Revenue in SEK (TTM)8.50m
- Net income in SEK-424.45m
- Incorporated2005
- Employees36.00
- LocationVicore Pharma Holding ABKornhamnstorg 53STOCKHOLM 111 27SwedenSWE
- Phone+46 317880560
- Websitehttps://vicorepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solar Foods Oyj | 201.90k | -112.68m | 1.49bn | 57.00 | -- | 6.64 | -- | 7,388.84 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 770.81m | 294.66m | 1.55bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Devyser Diagnostics AB | 242.80m | -25.20m | 1.70bn | 115.00 | -- | 4.97 | 1,210.96 | 6.98 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
| BioInvent International AB | 244.85m | -323.94m | 1.74bn | 124.00 | -- | 2.54 | -- | 7.10 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Thor Medical ASA | 93.85k | -55.28m | 1.79bn | 13.00 | -- | 3.98 | -- | 19,120.15 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| Egetis Therapeutics AB (publ) | 55.40m | -333.40m | 1.96bn | 40.00 | -- | 6.42 | -- | 35.38 | -0.9376 | -0.9376 | 0.1554 | 0.7725 | 0.0945 | 45.53 | 1.93 | 1,582,857.00 | -56.85 | -36.53 | -87.92 | -41.52 | 30.14 | 81.16 | -601.62 | -558.74 | 0.7971 | -45.06 | 0.249 | -- | -19.97 | -11.00 | -5.11 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -113.30m | 2.03bn | 5.00 | -- | 9.91 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 348.00k | -182.46m | 2.26bn | 41.00 | -- | 10.01 | -- | 6,491.90 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Vicore Pharma Holding AB | 8.50m | -424.45m | 2.98bn | 36.00 | -- | 3.11 | -- | 351.04 | -1.85 | -1.85 | 0.0371 | 3.40 | 0.0134 | -- | 2.04 | 293,137.90 | -66.65 | -49.13 | -71.78 | -54.58 | -- | -- | -4,992.90 | -1,107.81 | -- | -35.34 | 0.00 | -- | -- | -- | 45.77 | -- | -- | -- |
| Saniona AB | 743.21m | 573.47m | 3.60bn | 31.00 | 5.67 | 5.22 | 6.19 | 4.84 | 4.60 | 4.60 | 5.98 | 5.00 | 1.75 | -- | 121.92 | 33,782,040.00 | 135.23 | -38.47 | 170.81 | -45.71 | 90.13 | -55.15 | 77.16 | -156.43 | -- | -- | 0.0004 | -- | 1,887.36 | 115.50 | 296.96 | -- | -48.69 | -- |
| Hansa Biopharma AB | 222.27m | -529.25m | 3.94bn | 125.00 | -- | -- | -- | 17.74 | -6.44 | -6.44 | 2.73 | -0.8268 | 0.226 | 19.12 | 2.24 | 1,778,120.00 | -53.80 | -57.18 | -81.36 | -73.22 | 62.41 | 60.32 | -238.12 | -464.70 | 1.92 | -- | 1.10 | -- | 29.74 | 105.28 | 34.44 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Vicore Pharma Holding AB's reporting currency: Swedish Krona SEK
23.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2024 | 21.17m | 7.52% |
| Capital Research & Management Co. (World Investors)as of 13 Nov 2025 | 13.69m | 4.86% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2024 | 6.70m | 2.38% |
| Handelsbanken Fonder ABas of 31 Dec 2024 | 4.64m | 1.65% |
| Tredje AP-fondenas of 31 Dec 2024 | 3.90m | 1.39% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2025 | 3.61m | 1.28% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 3.60m | 1.28% |
| OrbiMed Advisors LLCas of 31 Dec 2024 | 3.20m | 1.14% |
| Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2024 | 2.60m | 0.92% |
| Swedbank Robur Fonder ABas of 31 Dec 2024 | 1.71m | 0.61% |
More ▼
Data from 31 Dec 2024 - 31 Jan 2026Source: FactSet Research Systems Inc.
